SCHEMBL5956823

SCHEMBL5956823

COC(=O)c1ccc2c(c1)OCC[C@@H]2SN

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
KDM4E B2RXH2 8/20 0.39
ALDH1A1 P00352 7/20 0.39
MAPT P10636 5/20 0.39
MEN1 O00255 2/20 0.39
TP53 P04637 2/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 4/20 0.38
TSHR P16473 2/20 0.38
LMNA P02545 2/20 0.38
HSD17B10 Q99714 2/20 0.38
MAPK1 P28482 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5956847 1.00 SMN1; SMN2 (0.39) SMN1; SMN2NPC1RAB9ACASP3SENP7
SCHEMBL5956820 1.00 SMN1; SMN2 (0.39) SMN1; SMN2NPC1RAB9ACASP3SENP7
SCHEMBL5956601 0.88 SMN1; SMN2 (0.40) SMN1; SMN2NPC1RAB9ACASP3SENP7
SCHEMBL5956765 0.88 SMN1; SMN2 (0.40) SMN1; SMN2NPC1RAB9ACASP3SENP7
SCHEMBL5956793 0.88 SMN1; SMN2 (0.40) SMN1; SMN2NPC1RAB9ACASP3SENP7
SCHEMBL785717 0.83 KDM4E (0.41) SMN1; SMN2NPC1RAB9ACASP3SENP7
SCHEMBL785716 0.83 KDM4E (0.41) SMN1; SMN2NPC1RAB9ACASP3SENP7
SCHEMBL5956844 0.82 SMN1; SMN2 (0.36) SMN1; SMN2NPC1RAB9ACASP3SENP7
SCHEMBL5956906 0.82 SMN1; SMN2 (0.36) SMN1; SMN2NPC1RAB9ACASP3SENP7
SCHEMBL5956834 0.82 SMN1; SMN2 (0.36) SMN1; SMN2NPC1RAB9ACASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1270570-B1 AMIDE COMPOUNDS AND USE THEREOF MITSUBISHI PHARMA CORP (JP) 2006-05-31 EP disclosed
US-6933305-B2 Amide compounds and use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-08-23 US disclosed
US-20030158413-A1 Amide compounds and use thereof MITSUBISHI PHARMA CORPORATION (JP) 2003-08-21 US disclosed
EP-1270570-A1 AMIDE COMPOUNDS AND USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158413-A1 Amide compounds and use thereof ROCK2, ROCK1, RHOT2 SMN1; SMN2 3300/4885NPC1 1207/4885RAB9A 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.